Ketamine, once known mainly as a veterinary anesthetic and club drug, is now being used more often for difficult to treat depression, anxiety, and post traumatic stress disorder. But this rapid increase in use has raised new safety concerns. A recent report from Becker’s Behavioral Health highlights growing worries about how ketamine is prescribed, who administers it, and the lack of consistent safety standards.

Key takeaways

  • Ketamine prescriptions for mental health conditions have surged in recent years, particularly for treatment resistant depression.
  • Safety experts warn about risks including dissociation, bladder damage, and potential for misuse.
  • Regulation varies widely by state and clinic, with some patients receiving infusions in unaccredited facilities.
  • The FDA has not approved ketamine for any psychiatric condition, though it has approved a related nasal spray called esketamine.
  • Many mental health professionals call for better training, monitoring, and reporting standards.

Why ketamine use is growing

In recent years, ketamine has drawn attention as a fast acting option for people who do not respond to standard antidepressants. Unlike traditional medications that can take weeks to work, ketamine can relieve symptoms within hours or days. That speed has made it attractive both to patients and to doctors looking for alternatives when other treatments fail. Clinics offering ketamine infusions have opened across the United States, and telemedicine platforms now prescribe at home lozenges or nasal sprays.

However, this growth has happened without the kind of regulatory guardrails that typically accompany new psychiatric treatments. According to the report from Becker’s Behavioral Health, the lack of standardized protocols is a major reason for the safety concerns now coming to light.

Safety risks associated with ketamine

Ketamine can cause a range of side effects. Short term effects include dizziness, nausea, and a temporary feeling of being disconnected from one’s body, known as dissociation. More serious risks include increases in blood pressure and heart rate, seizures, and bladder problems with repeated use. Some patients have reported developing cystitis, a painful bladder condition, after prolonged use.

There is also the risk of misuse. Ketamine is a controlled substance with known abuse potential. While most patients use it under medical supervision, the rise of at home formulations has made it easier for people to take it without proper monitoring. Experts quoted in the original report stress that patients should be carefully screened before starting ketamine therapy.

The regulatory gap

The Food and Drug Administration has not approved ketamine for any mental health condition. The only FDA approved form is esketamine, a nasal spray sold under the brand name Spravato, which is restricted to certified treatment centers. However, doctors can prescribe regular ketamine off label, meaning it can be used for conditions not listed on the label. This practice is legal but has led to wide variation in how clinics operate.

Some states have started to tighten rules. For example, California and Colorado have introduced legislation requiring licensed medical professionals to administer ketamine infusions and to follow specific safety protocols. But in many places, oversight remains minimal. The report notes that there is no national database tracking adverse events related to ketamine treatment, making it hard to know how often serious problems occur.

What patients should consider

If you are thinking about ketamine therapy, experts recommend asking several questions. Who will administer the treatment? Is the facility accredited? What training does the staff have? Are there plans for monitoring your vital signs during and after the session? It is also important to ask about the risks and to discuss your medical history honestly, including any history of substance use or heart problems.

Patients should also be aware that ketamine is not a first line treatment. It is generally reserved for people who have not gotten better after trying at least two other antidepressants. And while it can provide rapid relief, the effects usually do not last without continued therapy.

Frequently Asked Questions

Is ketamine approved by the FDA for depression?

No, ketamine itself is not FDA approved for depression or any other psychiatric condition. However, a closely related drug called esketamine (Spravato) is FDA approved for treatment resistant depression when used together with an oral antidepressant. Esketamine is only available through a restricted distribution system at certified treatment centers.

What are the most common side effects of ketamine therapy?

The most common side effects include temporary dissociation, dizziness, nausea, headache, and increased blood pressure. These effects usually resolve shortly after the treatment ends. More serious but less common risks include bladder problems, seizures, and psychological dependence, especially with long term or unsupervised use.

How can I find a safe ketamine clinic?

Look for clinics that are accredited by organizations such as the Joint Commission or the American Association for Accreditation of Ambulatory Surgery Facilities. Make sure the staff includes a board certified psychiatrist or anesthesiologist who is experienced in administering ketamine. Ask about their emergency protocols and how they monitor patients during treatment. Also check if the clinic requires a thorough medical and psychiatric evaluation before starting therapy.

The original report from Becker’s Behavioral Health underscores that while ketamine can be a valuable tool for some patients, its growing use demands greater attention to safety. Until stronger regulations are in place, patients and providers should proceed with caution.

This is an original report by Vital Signs Today, informed by reporting from Google News. Read the original source.

This article is for information only and is not medical advice. See our Medical Disclaimer.